Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up.
COVID-19
Fatigue
Follow-up
Health-related quality of life
Long COVID
Patient-reported outcomes
Post COVID
SARS-CoV-2
Subjective health
Symptoms
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
received:
24
04
2023
accepted:
14
08
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Most of the previous studies on health sequelae of COVID-19 are uncontrolled cohorts and include a relatively short follow-up. This population-based multi-center cohort study examined health consequences among individuals about 1 to 1.5 years after SARS-CoV-2 infection compared with non-infected. The study population consisted of adults (≥ 18 years) from four municipalities particularly affected by the COVID-19 pandemic in the year 2020 who completed a detailed follow-up questionnaire on health-related topics. Exposure was the SARS-CoV-2 infection status (based on IgG antibodies, PCR test, or physician-diagnosis of COVID-19) at baseline (May to December 2020). Outcomes assessed at follow-up (October 2021 to January 2022; mean: 452 days) included recurrent or persistent health complaints, incident diseases, health-related quality of life (PROMIS-29), subjective health, and subjective memory impairment. Logistic and linear regression models were adjusted for baseline sociodemographic and lifestyle characteristics (age, sex, municipality, education, smoking, body mass index), pre-existing health conditions (chronic disease/health problem, health-related activity limitation, depressive/anxiety disorder), and follow-up time. Among 4817 participants, 350 had a SARS-CoV-2 infection at baseline and 4467 had no infection at baseline or during follow-up. Those with an infection statistically significantly more often reported 7 out of 18 recurrent or persistent health complaints at follow-up: smell/taste disorders (12.8% vs. 3.4%, OR 4.11), shortness of breath (23.0% vs. 9.5%, 3.46), pain when breathing (4.7% vs. 1.9%, 2.36), fatigue (36.9% vs. 26.1%, 1.76), weakness in legs (12.8% vs. 7.8%, 1.93), myalgia/joint pain (21.9% vs. 15.1%, 1.53) and cough (30.8% vs. 24.8%, 1.34) and 3 out of 6 groups of incident diseases: liver/kidney (2.7% vs. 0.9%, 3.70), lung (3.2% vs. 1.1%, 3.50) and cardiovascular/metabolic (6.5% vs. 4.0%, 1.68) diseases. Those with an infection were significantly more likely to report poor subjective health (19.3% vs. 13.0%, 1.91), memory impairment (25.7% vs. 14.3%, 2.27), and worse mean scores on fatigue and physical function domains of PROMIS-29 than non-infected. Even after more than one year, individuals with SARS-CoV-2 infection showed an increased risk of various health complaints, functional limitations, and worse subjective well-being, pointing toward profound health consequences of SARS-CoV-2 infection relevant for public health.
Sections du résumé
BACKGROUND
Most of the previous studies on health sequelae of COVID-19 are uncontrolled cohorts and include a relatively short follow-up. This population-based multi-center cohort study examined health consequences among individuals about 1 to 1.5 years after SARS-CoV-2 infection compared with non-infected.
METHODS
The study population consisted of adults (≥ 18 years) from four municipalities particularly affected by the COVID-19 pandemic in the year 2020 who completed a detailed follow-up questionnaire on health-related topics. Exposure was the SARS-CoV-2 infection status (based on IgG antibodies, PCR test, or physician-diagnosis of COVID-19) at baseline (May to December 2020). Outcomes assessed at follow-up (October 2021 to January 2022; mean: 452 days) included recurrent or persistent health complaints, incident diseases, health-related quality of life (PROMIS-29), subjective health, and subjective memory impairment. Logistic and linear regression models were adjusted for baseline sociodemographic and lifestyle characteristics (age, sex, municipality, education, smoking, body mass index), pre-existing health conditions (chronic disease/health problem, health-related activity limitation, depressive/anxiety disorder), and follow-up time.
RESULTS
Among 4817 participants, 350 had a SARS-CoV-2 infection at baseline and 4467 had no infection at baseline or during follow-up. Those with an infection statistically significantly more often reported 7 out of 18 recurrent or persistent health complaints at follow-up: smell/taste disorders (12.8% vs. 3.4%, OR 4.11), shortness of breath (23.0% vs. 9.5%, 3.46), pain when breathing (4.7% vs. 1.9%, 2.36), fatigue (36.9% vs. 26.1%, 1.76), weakness in legs (12.8% vs. 7.8%, 1.93), myalgia/joint pain (21.9% vs. 15.1%, 1.53) and cough (30.8% vs. 24.8%, 1.34) and 3 out of 6 groups of incident diseases: liver/kidney (2.7% vs. 0.9%, 3.70), lung (3.2% vs. 1.1%, 3.50) and cardiovascular/metabolic (6.5% vs. 4.0%, 1.68) diseases. Those with an infection were significantly more likely to report poor subjective health (19.3% vs. 13.0%, 1.91), memory impairment (25.7% vs. 14.3%, 2.27), and worse mean scores on fatigue and physical function domains of PROMIS-29 than non-infected.
CONCLUSION
Even after more than one year, individuals with SARS-CoV-2 infection showed an increased risk of various health complaints, functional limitations, and worse subjective well-being, pointing toward profound health consequences of SARS-CoV-2 infection relevant for public health.
Identifiants
pubmed: 37605232
doi: 10.1186/s12889-023-16524-8
pii: 10.1186/s12889-023-16524-8
pmc: PMC10440884
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1587Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, W. H. O. Clinical case definition working group on post-COVID-19 condition a clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7.
doi: 10.1016/S1473-3099(21)00703-9
pubmed: 34951953
Hallek M, Adorjan K, Behrends U, Ertl G, Suttorp N, Lehmann C. Post-COVID syndrome. Dtsch Arztebl Int. 2023;120(4):48–55.
pubmed: 36633452
pmcid: 10060997
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911–23.
doi: 10.1038/s41591-022-01810-6
pubmed: 35585196
Callard F, Perego E. How and why patients made long Covid. Soc Sci Med. 2021;268: 113426.
doi: 10.1016/j.socscimed.2020.113426
pubmed: 33199035
pmcid: 7539940
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 . Accessed 15 Aug 2022.
National Institute for Health and Care Excellence (NICE). COVID-19 Rapid Guideline: Managing the Long-term Effects of COVID-19 (1.20 published on 03.11.2022). https://www.nice.org.uk/guidance/ng188 . Accessed 21 April 2023.
AWMF. S1-Leitlinie Post-COVID/Long-COVID. https://register.awmf.org/de/leitlinien/detail/020-027 . Accessed 29 Jan 2023.
Fernandez-de-Las-Penas C, Martin-Guerrero JD, Navarro-Pardo E, Rodriguez-Jimenez J, Pellicer-Valero OJ. Post-COVID functional limitations on daily living activities are associated with symptoms experienced at the acute phase of SARS-CoV-2 infection and internal care unit admission: a multicenter study. J Infect. 2022;84(2):248–88.
doi: 10.1016/j.jinf.2021.08.009
pubmed: 34375711
Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, et al. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51: 101549.
doi: 10.1016/j.eclinm.2022.101549
pubmed: 35875815
pmcid: 9289961
Greer N, Bart B, Billington CJ, Diem SJ, Ensrud KE, Kaka A, et al. COVID-19 postacute care major organ damage: a systematic review. BMJ Open. 2022;12(8): e061245.
doi: 10.1136/bmjopen-2022-061245
pubmed: 36002211
Wrona M, Skrypnik D. New-onset diabetes mellitus, hypertension, dyslipidaemia as sequelae of COVID-19 infection-systematic review. Int J Environ Res Public Health. 2022;19(20):13280.
doi: 10.3390/ijerph192013280
pubmed: 36293857
pmcid: 9602450
Global Burden of Disease Long Covid Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15.
doi: 10.1001/jama.2022.18931
pmcid: 9552043
Franco JVA, Garegnani LI, Oltra GV, Metzendorf MI, Trivisonno LF, Sgarbossa N, et al. Long-term health symptoms and sequelae following SARS-CoV-2 infection: an evidence map. Int J Environ Res Public Health. 2022;19(16):9915.
doi: 10.3390/ijerph19169915
pubmed: 36011562
pmcid: 9408764
Santos-Hovener C, Busch MA, Koschollek C, Schlaud M, Hoebel J, Hoffmann R, et al. Seroepidemiological study on the spread of SARS-CoV-2 in populations in especially affected areas in Germany - study protocol of the CORONA-MONITORING lokal study. J Health Monit. 2020;5(Suppl 5):2–16.
pubmed: 35146295
pmcid: 8734078
Santos-Hovener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Euro Surveill. 2020;25(47):2001752.
doi: 10.2807/1560-7917.ES.2020.25.47.2001752
pubmed: 33243353
pmcid: 7693167
Heidemann C, Reitzle L, Schmidt C, Fuchs J, Prutz F, Scheidt-Nave C. Non-utilisation of health care services during the COVID-19 pandemic: results of the CoMoLo study. J Health Monit. 2022;7(Suppl 1):2–17.
pubmed: 35356069
pmcid: 8939005
Neuhauser H, Buttmann-Schweiger N, Ellert U, Fiebig J, Hövener C, Offergeld R, et al. Seroepidemiologische Studien zu SARS-CoV-2 in Stichproben der Allgemeinbevölkerung und bei Blutspenderinnen und Blutspendern in Deutschland – Ergebnisse bis August 2021. https://edoc.rki.de/handle/176904/8743 . Accessed 21 Apr 2023.
Jessen F, Wiese B, Cvetanovska G, Fuchs A, Kaduszkiewicz H, Kolsch H, et al. Patterns of subjective memory impairment in the elderly: association with memory performance. Psychol Med. 2007;37(12):1753–62.
doi: 10.1017/S0033291707001122
pubmed: 17623488
Alonso J, Bartlett SJ, Rose M, Aaronson NK, Chaplin JE, Efficace F, et al. The case for an international patient-reported outcomes measurement information system (PROMIS(R)) initiative. Health Qual Life Outcomes. 2013;11:210.
doi: 10.1186/1477-7525-11-210
pubmed: 24359143
pmcid: 3879205
Fischer F, Gibbons C, Coste J, Valderas JM, Rose M, Leplege A. Measurement invariance and general population reference values of the PROMIS profile 29 in the UK, France, and Germany. Qual Life Res. 2018;27(4):999–1014.
doi: 10.1007/s11136-018-1785-8
pubmed: 29350345
Patient-Reported Outcomes Measurement Information System. PROMIS ADULT PROFILE INSTRUMENTS - A brief guide to the PROMIS® Profile instruments for adult respondents. https://staging.healthmeasures.net/images/PROMIS/manuals/PROMIS_Adult_Profile_Scoring_Manual.pdf . Accessed 29 Sep 2022.
Statistical Office of the European Union (Eurostat). International Standard Classification of Education (ISCED). https://ec.europa.eu/eurostat/statistics-explained/index.php?title=International_Standard_Classification_of_Education_(ISCED ). Accessed 15 Aug 2022.
Cox B, van Oyen H, Cambois E, Jagger C, le Roy S, Robine JM, et al. The reliability of the minimum European health module. Int J Public Health. 2009;54(2):55–60.
doi: 10.1007/s00038-009-7104-y
pubmed: 19183846
Kroenke K, Spitzer RL, Williams JB, Lowe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–21.
pubmed: 19996233
Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974;99(5):325–32.
doi: 10.1093/oxfordjournals.aje.a121617
pubmed: 4825599
van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219–42.
doi: 10.1177/0962280206074463
pubmed: 17621469
O’Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55: 101762.
doi: 10.1016/j.eclinm.2022.101762
pubmed: 36474804
Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al. Long COVID through a public health lens: an umbrella review. Public Health Rev. 2022;43:1604501.
doi: 10.3389/phrs.2022.1604501
pubmed: 35359614
pmcid: 8963488
Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. Eur J Epidemiol. 2022;37(5):539–48.
doi: 10.1007/s10654-022-00847-8
pubmed: 35211871
pmcid: 8872922
Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934–46.
doi: 10.1001/jama.2023.8823
pubmed: 37278994
pmcid: 10214179
Peter RS, Nieters A, Krausslich HG, Brockmann SO, Gopel S, Kindle G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379: e071050.
doi: 10.1136/bmj-2022-071050
pubmed: 36229057
Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, et al. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. EClinicalMedicine. 2022;53: 101651.
doi: 10.1016/j.eclinm.2022.101651
pubmed: 36133318
pmcid: 9482331
de Oliveira Almeida K, Nogueira Alves IG, de Queiroz RS, de Castro MR, Gomes VA, Santos Fontoura FC, et al. A systematic review on physical function, activities of daily living and health-related quality of life in COVID-19 survivors. Chronic Illn. 2022;19:279. https://doi.org/10.1177/17423953221089309 .
doi: 10.1177/17423953221089309
Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452–61.
doi: 10.1016/S0140-6736(22)01214-4
pubmed: 35934007
pmcid: 9352274
Kubota T, Kuroda N, Sone D. Neuropsychiatric aspects of long COVID: A comprehensive review. Psychiatry Clin Neurosci. 2023;77(2):84–93.
doi: 10.1111/pcn.13508
pubmed: 36385449
Velichkovsky BB, Razvaliaeva AY, Khlebnikova AA, Manukyan PA, Kasatkin VN. Attention and memory after COVID-19 as measured by neuropsychological tests: systematic review and meta-analysis. Acta Psychol (Amst). 2023;233: 103838.
doi: 10.1016/j.actpsy.2023.103838
pubmed: 36657196
Wion RK, Hill NL, Reed Bell T, Mogle J, Yates J, Bhang I. The role of cognitive self-report measure type in predicting cognitive decline among older adults: a systematic review. J Geriatr Psychiatry Neurol. 2022;35(4):487–511.
doi: 10.1177/08919887211023591
pubmed: 34151643
Pike KE, Cavuoto MG, Li L, Wright BJ, Kinsella GJ. Subjective cognitive decline: level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies. Neuropsychol Rev. 2022;32(4):703–35.
doi: 10.1007/s11065-021-09522-3
pubmed: 34748154
Huang Y, Pinto MD, Borelli JL, Asgari Mehrabadi M, Abrahim HL, Dutt N, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler looking for clarity in the haze of the pandemic. Clin Nurs Res. 2022;31(8):1390–8.
doi: 10.1177/10547738221125632
pubmed: 36154716
pmcid: 9510954
Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423–33.
doi: 10.1038/s41380-022-01614-7
pubmed: 35668159
Shrestha AB, Mehta A, Pokharel P, Mishra A, Adhikari L, Shrestha S, et al. Long COVID Syndrome and cardiovascular manifestations: a systematic review and meta-analysis. Diagnostics (Basel). 2023;13(3):491.
doi: 10.3390/diagnostics13030491
pubmed: 36766599
Petersen EL, Gossling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: the Hamburg City Health Study COVID programme. Eur Heart J. 2022;43(11):1124–37.
doi: 10.1093/eurheartj/ehab914
pubmed: 34999762
pmcid: 8755397
Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268–70.
doi: 10.1016/j.it.2022.02.008
pubmed: 35272932
pmcid: 8901423
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.
doi: 10.1038/s41579-022-00846-2
pubmed: 36639608
pmcid: 9839201
Iwasaki A, Putrino D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis. 2023;23(4):393–5.
doi: 10.1016/S1473-3099(23)00053-1
pubmed: 36967698
pmcid: 9928485
Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18(5): e1010359.
doi: 10.1371/journal.ppat.1010359
pubmed: 35617421
pmcid: 9176759
Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263–4.
doi: 10.1016/S0140-6736(22)00941-2
pubmed: 35717982
pmcid: 9212672